IL122372A - Substituted piperidine-2, 6-diones, their preparation and their use for preparation of a drug - Google Patents

Abstract

Substituted piperidine - 2, 6-diones of the formula wherein Z denotes -C(R1R2)-CH2- or -C(R1) = CH-, R1 represents phthalimide (when Z = -C(R1R2)-CH2-), or a phthalimide radical which is singly - or doubly - substituted with hydroxy, methoxy or amino groups (when Z = -C(R1) = CH), R2 denotes hydrogen or a C1-C6 alkyl group, R3 is hydrogen, a C1-C6 alkyl group or a (hetero) aromatic ring system, and R4 represents a C1-C6 alkyl group or a (hetero) aromatic ring. 3491 כ" ו בכסלו התשס" ג - December 1, 2002

Description

122372/3 Substituted piperidine-2,6-diones, their preparation and their use for preparation of a drug GRUNENTHAL GmbH C. 108942 The present invention relates to compounds analogous to thalidomide from the class comprising piperidine-2,6-diones, to a method of preparing them and to their use for the preparation of a drug.

The excessive formation of the cytokinin TNF-a (tumor necrosis factor a) plays a central part in the pathogenesis of graft-versus-host syndrome, of multiple sclerosis, or transplant rejection, aphthous stomatitis, erythema nodosum leprosum, morbus Boeck, rheumatoid arthritis and a series of other diseases which are associated with inflammatory symptoms. One basis for the therapy of these diseases consists of the targeted suppression of the release of TNF-cc, by administering immunosuppressant or immunomodulating active ingredients, such as dexamethasone, pentoxifylline or thalidomide for example.

A distinction must be made, however, between indications which necessitate a general immunosuppression and those for which the advantages and disadvantages of immunosuppression have to be weighed up. In the treatment of aphthous stomatitis, thalidomide has been shown to be superior to classical immunosuppressants. Other examples of diseases in which thalidomide has exhibited good efficacy without resulting in a general immunosuppression include cutaneous lupus erythematosus (H+G 69, 816 to 822 (1994)), pyoderma gangrenosum and orogenital ulcers with morbus e cet (The Lancet, 20.05.89, 1093 to 1095). The pathogenetic factors of these lesions, which are restricted to the skin and mucous membranes, are endogenous mediators which have effects on the endothelium and on circulating leukocytes. Under the influence of TNF-a and other cytokinins, there is a marked increase in the adhesiveness of the endothelium in relation to leukocytes, which makes a definitive contribution to the development of vasculitis. With systemic pathogens, the effect of thalidomide itself is restricted to the skin and mucous membranes, which necessitates (additional) immunosuppression. Examples thereof include systemic lupus erythematosus, which apart from dermal phenomena also causes life-threatening changes of the internal vessels, particularly of the kidneys; type II leprareaction, involving the eyes and/or the joints, as well as morbus Behget, involving the eyes and/or joints.

Substances which, like thalidomide, suppress this alteration of the endothelium, but which at the same time completely or partly block reactions of the specific cellular immune defence, can constitute an important advance in the therapy of said systemic pathogens. One key messenger substance of the cellular immune response is interleukin-2, on which the proliferation of antigen-specific lymphocytes depends.

When developing new drags, one aim is therefore to put into effect the antiinflammatory properties of thalidomide jointly with immunosuppressive active components which thalidomide on its own does not have in its clinical application.

The underlying object of the present invention was to develop compounds analogous to thalidomide from the class comprising piperidine-2,6-diones, which inhibit the inflammation-triggered release of TNF-a as well as the antigen-induced synthesis of interleukin-2.

It has been found that the compounds according to the invention fulfill the stated requirements.

The present invention therefore relates to piperidine-2,6-diones, which are substituted in positions 3 and 5, of general formula (I) wherein Z represents one of the groups R1 R 2 or \ / °r — C — CH„- wherein the carbon atom with substituent R1 is bonded to the carbonyl group, and in which R1 denotes a phthalimide radical (when Z is -C^R^-CFk-) or a phthalimide radical which is singly- or doubly-substituted with hydroxy, methoxy or amino groups (when Z represents -CiR1) = CH-), R2 is hydrogen or a Ci-Ce alkyl (straight chain or branched), R3 represents hydrogen, a C1-C6 alkyl group (straight chain or branched), or an aromatic or heteroaromatic ring system, and R4 denotes a Ci-C6 alkyl group (straight chain or branched), or an aromatic or heteroaromatic ring system.

Of the piperidine-2,6-diones of formula (I), in which Z denotes -C(R1R2)-CH2-, R1 denotes phthalimide and R2 and R3 denote hydrogen, the compound in which R4 is phenyl is particularly preferred.

Of the piperidine-2,6-diones of formula (I), in which Z is -C(Rl) = CH-, R3 denotes ethyl and R4 denotes phenyl, the compound in which R1 is 3,4-dimethoxyphthalimide is particularly preferred.

The present invention further relates to a method of preparing compounds analogous to thalidomide from the class comprising piperidine-2,6-diones, of general formula (I).

Compounds of general formula (I) where Z = can be prepared by the condensation of phthalic anhydride with a substituted glutamic acid, such as 4-phenylglutamic acid or 4-methylglutamic acid for example, in an organic solvent, preferably pyridine, cyclisation of the product in acetic anhydride and subsequent conversion into the imide. Conversion of the anhydride into the imide is effected here by fusion with urea.

These target compounds of formula (I) can also be obtained by the reaction of phthalic anhydride with a 5-substituted 3-anMnoglutarimide, preferably by heating in acetic acid.

Compounds of general formula (I) where Z = -CiR^CH- can be prepared by the condensation of a substituted phthalic anhydride, such as 3,4-dimethoxyphthalic anhydride for example, with 5-substituted 3-amino-3,4-dehydropiperidine-2,6-diones, such as 3-amino-5-ethyl-5-phenyl-glutaconimide for example, in an organic solvent, for example acetic acid.

Example 1 2-(5-methyl-2,6-dioxo-piperidin-3-yl)-l,3-dihydro-2H-isoindole-l,3-dione (1) 2.00 g (11 mmoles) 4-methylglutamic acid and 1.95 g (13 mmoles) phthalic anhydride were heated for 6 hours under reflux in 15 ml of dry pyridine. After removing the solvent by distillation, the residue was heated to boiling for 1 hour in 10 ml acetic anhydride. The solid which precipitated on cooling was filtered off under suction and the filtrate was concentrated. After treating the filtrate with ether, the precipitate which formed was filtered off under suction and the purified precipitates were recrystallised from absolute toluene. 2.00 g (7 mmoles) of the crystalline material and 0.23 g (3.8 mmoles) urea were well mixed and were fused on an oil bath at about 200°C for 30 minutes. The solidified melt was heated briefly to boiling, with 4 ml acetic anhydride and 6 ml ethanol in succession. The precipitated solid was filtered off under suction and recrystallised from DMF/water. 1.35 g (67 % theoretical) 2-(5-methyl-2,6-dioxo-piperidin-3-yl)-l,3-dihydro-2H-isoindole-l,3-dione (1) were obtained, with a melting point of 270 to 272°C.

Example 2 2-(5-phenyl-2,6-dioxo-piperidin-3 -yl)- 1 ,3 -dihydro-2H-isoindole- 1 ,3 -dione (2) 3.00 g (12 mmoles) 4-phenylglutamic acid and 2.12 g (14 mmoles) phthalic anhydride were heated for 6 hours under reflux in 40 ml of dry pyridine. After removing the solvent by distillation, the residue was taken up in 50 ml of 5 % HC1 and extracted with ethyl acetate. The organic phase was washed with water, decolourised with activated carbon and dried over sodium sulphate. After removing the solvent by distillation, the residue was heated under reflux for 1 hour in 40 ml acetic anhydride. The solution was subsequently concentrated and treated with ether. The precipitate formed was filtered off under suction and was recrystallised from dry toluene. 2.00 g (6 mmoles) of the crystalline material and 0.19 g (3 mmoles) urea were fused on an oil bath at about 200°C for 30 minutes. The solidified melt was heated briefly to boiling, with 4 ml acetic anhydride and 8 ml ethanol in succession. The precipitated solid was recrystallised from DMF/water. 0.80 g (40 % theoretical) 2-(5-phenyl-2,6-dioxo-piperidin-3-yl)-l,3-dihydro-2H-isoindole-l,3-dione (2) were obtained, with a melting point of 228 to 231°C.

Example 3 2-(5-ethyl-5-phenyl-2,6-dioxo-piperidin-3-yl)-l,3-dihydro-2H-isoindole-l,3-dione (3) 1.00 g (4 mmoles) 3-amino-5-ethyl-5-phenyl-glutaconimide were dissolved in 40 ml of anhydrous ethanol, and the solution was treated with 0.1 g of palladinised charcoal (10 % Pd/C) and stirred for 8.5 hours in a hydrogen atmosphere. The solution was subsequently filtered from the catalyst and the filtrate was evaporated to dryness. The residue was heated for 4 hours under reflux with 0.70 g ( 5 mmoles) phthalic anhydride in 40 ml glacial acetic acid. After removing the solvent by distillation, the residue was recrystallised from ethanol. 0.99 g (63 % theoretical) 2-(5-ethyl-5-phenyl-2,6-dioxo-piperidin-3-yl)-l,3-dihydro-2H-isoindole-l,3-dione (3) were obtained, with a melting point of 174 - 177°C.

Example 4 2-(5-ethyl-5-phenyl-2,6-dioxo-l,2,5,6-tetrahydropyridin-3-yl)-4,5-dimethoxy-l,3-dihydro-2H-isoindole-l,3-dione (4) 0.45 g (2 mmoles) 3-amino-5-ethyl-5-phenyl-glutaconimide and 0.45 g (2 mmoles) 4,5-dimethoxyphthalic anhydride were heated for 5 hours under reflux in 15 ml glacial acetic acid. The solution was subsequently evaporated to dryness and the residue was recrystallised from ethanol. 0.55 g (67 % theoretical) 2-(5-ethyl-5-phenyl-2,6-dioxo-l,2,5,6-tetrahydropyridin-3-yl)-4,5-dimethoxy-l,3-dihydro-2H-isoindole-l,3-dione (4) were obtained, with a melting point of 203 - 205°C. 122372/2 - 7 - The compounds according to the invention are toxicologically harmless and are therefore suitable as pharmaceutical active ingredients. Accordingly, the present invention also relates to compounds analogous to thalidomide from the class comprising piperidine-2,6-diones, of general formula (I) for use as an active ingredient in a drug, preferably as suppressors of the inflammation-triggered release of TNF-ct and of the antigen-induced synthesis of interleukin-2.

In addition to at least one compound of general formula (I), drugs according to the invention contain support materials, fillers, solvents, diluents, colorants and/or binders. The selection of these adjuvant substances and of the amounts to be used depends on whether the drug is to be administered orally, intravenously, intraperitoneally, intradermally, intramuscularly, intranasally, buccally or locally. Preparations in the form of tablets, lozenges, dragees, capsules, granules, drops, juices or syrups are suitable for oral administration, and solutions, suspensions, readily reconstitutable dry preparations and sprays are suitable for parenteral and topical administration and for administration by inhalation. Compounds according to the invention in a deposit in dissolved form, in a carrier film or in a patch, optionally with the addition of agents which promote dermal penetration, are examples of suitable percutaneous forms of application. The compounds according to the invention can be released in a delayed manner from forms of preparations which can be employed orally or percutaneously.

The amount of active ingredient to be administered to the patient depends on the weight of the patient, on the type of application, on the indication and on the degree of severity of the illness. 1 to 150 mg/kg of at least one compound analogous to thalidomide of formula ( is usually a Pharmacological investigations The release of TNF-a can be investigated in vitro on human mononuclear cells of the peripheral blood (T cells, B cells and monocytes), after stimulation with lipopolysaccharide (LPS). LPS is a constituent of the bacterial cell wall and stimulates monocytes and macrophages.

Apart from stimulation with LPS, the release of TNF-a can also be provoked by the stimulation of human mononuclear cells of the peripheral blood by T cells of monoclonal antibodies which react specifically with activation antigens (antiCD2-antiCD28) or by the bacterial antigen toxic shock syndrome toxin- 1 TSST-1. Apart from the release of TNF-a, these stimulants result, amongst other effects, in the formation of interleukin-2 (11-2).

LPS stimulation of mononuclear cells: effect on TNF-a The release of TNF-a can be investigated in vitro on human mononuclear cells of the peripheral blood, namely T cells, B cells and monocytes, after stimulation with lipopolysaccharide (LPS). LPS is a constituent of the bacterial cell wall and stimulates monocytes and macrophages.

Mononuclear cells were obtained from the heparin-treated blood of at least three volunteer donors. For this purpose, 20 ml blood in each case were separated by known methods via a Ficoll-Paque gradient, and the cells were harvested and washed three times with a cell culture medium. This cell culture medium consisted of RPMI 1640 medium, supplemented with 2 raM glutamine (Life Technologies, Eggenstein), 10 % foetal calf serum (Life Technologies), 50 μg l streptomycin (Sigma, Deisenhofen), 50 IU/ml penicillin (Sigma) and 100 μΜ β-mercaptoethanol (Merck, Darmstadt). The mononuclear cells were finally taken up in 15 ml cell culture medium and were divided into 1 ml batches in sterile 24-hole incubation plates (Sigma). 1 μΐ dimethylsulphoxide (DMSO, Merck) or 1 μΐ of a solution of the test substance (in DMSO; final concentration in the test: 0.5; 5; 12.5 and 50 μg/ml) was added to each of the 1 ml batches and the batches were incubated for one hour in a C02 incubation cabinet (5 % C02, 90 % atmospheric humidity). 2.5 μg LPS (from E. coli 0127: B8, Sigma) was subsequently added to each batch with the exception of the controls. Incubation of the cultures was continued for 20 hours. Following the tests, the concentration of TNF-a in the cell culture supernatant liquors was determined using commercial ELISA tests (Boehringer Mannheim). The magnitude of the TNF-a inhibition was calculated from the measured values of the control batches which were not treated with active ingredient and from the batches incubated with the test compounds. The concentrations which resulted in 50 % inhibition of the release of TNF-a (the IC50 values) were calculated by means of linear regression analysis.

Table 1 shows the inhibiting effect of the compounds according to the invention on the LPS-induced release of TNF-a: Table 1 Example No. Inhibition of the release of ICso fog/ml] TNF-a (in %) at a final concentration of 50 μg/ml in the test 1 48 % not determined 2 69 % 8.7 3 80 % 11.0 4 90 % 2.0 Stimulation of T cells: inhibition of H-2 The release of interleukin-2 can be investigated by the in vitro stimulation of human mononuclear cells of the peripheral blood, which in addition to T cells also contains B cells and monocytes. By polyclonal stimulation via constant epitopes of the T cell receptor or via what are termed accessory signal-transmitting surface molecules, a measurable range is obtained which is more pronounced than that from the antigen stimulation of smaller T cell populations. A combination of two such accessory signals was used, namely those transmitted via surface molecules CD2 and CD8.

Mononuclear cells were obtained from the heparin-treated blood of at least three volunteer donors. For this purpose, 20 ml blood in each case were separated by known methods via a Ficoll-Paque gradient, and the cells were harvested and washed three times with a cell culture medium. This cell culture medium consisted of RPMI 1640 medium, supplemented with 2 raM glutamine (Life Technologies, Eggenstein), 10 % foetal calf serum (Life Technologies), 50 μ /l streptomycin (Sigma, Deisenhofen), 50 IU/ml penicillin (Sigma) and 100 μΜ β-mercaptoethanol (Merck, Darmstadt). The mononuclear cells were finally taken up in 15 ml cell culture medium and were divided into 1 ml batches in sterile 24-hole incubation plates (Sigma). 1 μΐ dimethylsulphoxide (DMSO, Merck) or 1 μΐ of a solution of the test substance (in DMSO; final concentration in the test: 0.5; 5; 12.5 and 50 μg/ml) was added to each of the 1 ml batches and the batches were incubated for one hour in a C02 incubation cabinet (5 % C02, 90 % atmospheric humidity). 0.1 μg ml of monoclonal antibodies (clone no. AICD2.M1 from Prof. Dr. Meuer; anti-CD28 from CLB, Amsterdam) was subsequently added to each batch with the exception of the controls. Incubation of the cultures was continued for 20 hours. Following the tests, the concentration of 11-2 in the cell culture supernatant liquors was determined using commercial ELISA tests (Boehringer Mannheim). The magnitude of the 11-2 inhibition was calculated from the measured values of the control batches which were not treated with active ingredient and from the batches incubated with the test compounds.

Under these conditions, at a concentration of 50 μg ml, the substance from example 4 inhibited the CD2/CD28-stimulated synthesis of Π-2 by 86 ± 6 %. When using staphylococcus superantigen (from E. coli 0127: B8; Sigma, Deisenhofen) TSST-1 (0.1 g/ml) as a T cell stimulus, the 11-2 synthesis was inhibited by 77 ± 20 %.

The above investigations show that compounds analogous to thalidomide from the class comprising piperidine-2,6-diones of formula (I) inhibit both the inflammation-triggered release of TNF-a and the antigen-induced synthesis of interleukin-2.

Claims (7)

Claims

1. ) Substituted piperidine-2,6-diones of formula (I) wherein Z denotes -QR'R^-CIt- or -C(R!) = CH-, R1 represents phthalimide (when Z = -001¾2)-Ο¼-), or a phthalimide radical which is singly- or doubly-substituted with hydroxy, methoxy or amino groups (when Z = -C(Kl) = CH-), R2 denotes hydrogen or a Ci-C6 alkyl group, R3 is hydrogen, a Ci-C6 alkyl group or a (hetero)aromatic ring system, and R4 represents a Ci-Ce alkyl group or a (hetero)aromatic ring.

2. ) Substituted piperidine-2,6-diones of formula (I) according to claim 1, characterised in that Z is -CCR'R^CHa.-, R1 denotes phthalimide, R2 represents hydrogen, R3 denotes hydrogen or ethyl, and R4 represents methyl or phenyl.

3. ) Substituted piperidine-2,6-diones of formula (I) according to claim 1, characterised in that Z is -C(R ) = CH-, R1 denotes 3,4-dimethoxyphthalimide, R3 represents ethyl, and R4 represents phenyl. 122372/2 - 13 -

4. ) A method of preparing substituted piperidine-2,6-diones of formula (I) according to claims 1 or 2, characterised in that a phthalic anhydride is condensed with a substituted glutamic acid, the product is cyclised to form the anhydride, and the latter is converted into the imide.

5. ) A method of preparing substituted piperidine-2,6-diones of formula (Γ) according to claims 1 to 3, characterised in that a phthalic anhydride is condensed with substituted 3 -aminoglutaconimides or 5-substituted 3- ammoglutarimides.

6. ) Substituted piperidine-2,6-dione of formula (I) according to claims 1 to 3 for use as an active ingredient in a drug.

7. ) The substituted piperidine-2,6-dione according to claim 6, characterised in that the drug is an immunomodulator. For the Applicants, REINH S By: